welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposis
In a randomized clinical chemoprevention trial, a combination of celecoxib and diflouromethylornithine resulted in a nonsignificant benefit among patients with familial adenomatous polyposis when adenoma count in a defined area was used as the primary endpoint. However, the combination was well tolerated, and a secondary measure of adenoma burden using a video-based global assessment showed a significant incremental benefit.
expertly curated content related to this topic
- Sapna Syngal, MD, MPHCurrent Positions: Director, Gastrointes...
- Chemoprevention of Colorectal NeoplasiaBACKGROUND : Colorectal cancer is a comm...
- Dacarbazine-Doxorubicin Therapy Ameliorated an Extremely Aggressive Mesenteric Desmoid Tumor Associated with Familia...A 30-year-old man with familial adenomat...
- Lawrence C. Rusin, MDSpecialities/Interests: Anorectal Diseas...
- Vanderbilt – Ingram Cancer CenterVanderbilt-Ingram Cancer Center is one o...
- Successful Radiofrequency Ablation of an Anterior Abdominal Wall Desmoid in Familial Adenomatous PolyposisBACKGROUND : Desmoid tumours are an impo...
- Steven GallingerHead of the Hepatobiliary and pancreatic...
English
Portuguese
Spanish